Biodesix Announces Phase 3 Clinical Trial Collaboration with Kadmon
News Mar 02, 2012
Biodesix Inc. announce a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 non-small cell lung cancer (NSCLC) study of Kadmon’s KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3, and SRC.
The study incorporates an exploratory analysis using VeriStrat, a commercially available, blood-based test that is currently used to help physicians guide treatment for patients with non-small cell lung cancer. VeriStrat testing will be performed on serum samples from the study to assess the test’s utility in identifying patients with better or worse outcomes following treatment with KD019. As a multiple TKI with superior potency against wild-type EGFR, KD019 is designed to improve overall survival compared to erlotinib.
“We are very pleased to work with Kadmon on this program,” commented Paul Beresford, Ph.D., Biodesix’ Vice President of Business Development and Strategic Marketing. “Our successful collaboration may bring a personalized approach to this exciting new therapy.”
Over the past year Biodesix has forged multiple partnerships with bio-pharmaceutical companies to examine VeriStrat’s utility with innovative oncology therapies and to discover novel diagnostic tests.
John Ryan, Ph.D., M.D., Chief Medical Officer of Kadmon, said, “This collaboration is aligned with our strategic vision to advance leading-edge science and therapies targeting multiple pathways of proliferation and survival in disease.”